Lords Mark Industries Limited (KRATOSENER) is currently trading at 82.28 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Lord's Mark Industries Limited is a BSE-listed, diversified Indian conglomerate focused on MedTech (IVD, diagnostics, AI-enabled devices, genomics) and Renewable Energy (solar EPC and LED), formed through a 2025 NCLT-approved reverse merger and active expansion via acquisitions, institutional partnerships and government contracts across India and export markets. The company reports a substantial government-anchored renewable order book (~₹2,000 crore) within a broader ₹3,000+ crore pipeline and has committed to delivering 500 MW of solar capacity over seven years, signalling large public-programme execution capability and material near-term revenue visibility in the Renewables vertical. Lord's Mark has actively commercialised AI- and IoT-enabled healthcare products: an 85% acquisition of Renalyx (AI dialysis with CE certification), an AI-powered breast-screening wearable, cloud-connected Renal Command Center, and a USD 1 million US order for remote patient monitoring, demonstrating productised AI/IoT solutions in revenue-generating deployments. Management targets rapid scale: a forecasted revenue rise from ₹710 crore (FY25) to ₹2,638 crore (FY29) with EBITDA expanding and net debt collapsing towards near-zero, supported by planned capital raises (₹500 crore FPO/preferential) and a ₹325 crore manufacturing capex allocation, driving the demerger and growth roadmap through FY29. The firm has built institutional IP and regulatory advantages—CDSCO single-roof manufacturing licence, 139 trademarks and multiple exclusive tech transfers with IIT-Bombay, BARC and C-MET—positioning Lord's Mark to substitute imports, win government programmes and expand exports into the US, GCC and SAARC markets.

Over the past 52 weeks, Lords Mark Industries Limited has traded between a low of ₹60.00 and a high of ₹99.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Lords Mark Industries Limited has a market capitalization of approximately 3,476.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Lords Mark Industries Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,476.54 Cr, Lords Mark Industries Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Lords Mark Industries Limited operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Lords Mark Industries Limited is 41.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Lord's Mark reported consolidated net profit of Rs 50.44 crore for the six months ended September 30, 2026. It reported a consolidated loss of Rs 2.14 crore in the six months ended September 30, 2025. Total comprehensive income was also Rs 50.44 crore because no other comprehensive income was reported.

Lord's Mark Industries plans January 2027 launches for a sickle-cell screening product and a breast-cancer screening device. The sickle-cell launch is conditional on the manufacturing licence being issued, while Lord's Mark Industries said the breast-cancer device had completed regulatory approvals.

Lord's Mark reported unaudited consolidated net profit of Rs 50.4388 crore for the six months ended September 30, 2026. The corresponding six-month period ended September 30, 2025 recorded a consolidated loss of Rs 2.1405 crore.

Lord's Mark reported a Rs 68.29 crore operating cash outflow for the half year ended September 30, 2026. Its cash-flow statement records a Rs 294.61 crore increase in short-term loans and advances and other current assets, which outweighed other operating cash movements.